RCAMU
EGRX

Rothschild & Co Asset Management US’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Rothschild & Co Asset Management US’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-161,444
Closed -$6.5M – 383
2018
Q4 		$6.5M Sell
161,444
-238,793
-60% -$12.3M 0.08% 284
2018
Q3 		$27.7M Sell
400,237
-7,314
-2% -$554K 0.28% 146
2018
Q2 		$30.8M Buy
+407,551
New +$25.6M 0.33% 110

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Rothschild & Co Asset Management US's EGRX Position: Q1 2019 in Review

Rothschild & Co Asset Management US sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2019, closing a stake of 161,444 shares — an estimated $6.5M sold.

Rothschild & Co Asset Management US first reported a position in EGRX in Q2 2018 and held it in 3 quarters. The position peaked at $30.8M in Q2 2018. 182 funds tracked by Wall St. Rank hold EGRX as of Q1 2019.

  • Rothschild & Co Asset Management US reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 161,444 Eagle Pharmaceuticals, Inc. shares in Q1 2019, an estimated $6.5M.
  • Rothschild & Co Asset Management US first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
  • Rothschild & Co Asset Management US's Eagle Pharmaceuticals, Inc. position peaked at $30.8M in Q2 2018.
  • 182 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2019.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2019, filed 8 May 2019.